B-type Natriuretic Peptide: A Diagnostic Biomarker for a Hemodynamically Significant PDA
DOI:
https://doi.org/10.3889/oamjms.2022.7139Keywords:
Patent ductus arteriosus, Preterm infant, B-type natriuretic peptide, EchocardiogramAbstract
Background: B-type natriuretic peptide (BNP) it has been reported to be a useful biomarker for the severity of hemodynamically significant patent ductus arteriosus (HsPDA) in premature infants. Objective: To assess serum levels of BNP in premature neonates with echocardiographically-confirmed hemodynamically significant and non-significant PDA (HnsPDA) and to explore the effect of PDA on left ventricular function. We also aimed to detect the level of BNP that differentiates between HsPDA and HnsPDA. Patients and methods: This was a cross-sectional observational study conducted on 73 randomly selected preterm neonates with HsPDA or hemodynamically nonsignificant PDA (HnsPDA), between May 2017 and May 2018. Echocardiography was done. BNP was measured using enzyme linked immunosorbent assay Results: There was no affection of left ventricular function in either group (LA/Ao ratio, FS, LVESD and LVEDD). PDA size, PFO size and PAP were significantly larger in HsPDA (p<0.001, p=0.001, p<0.001 respectively). Levels of BNP were significantly higher in HsPDA and correlated with the size of the PDA. At a cut-off value of 160.5 pg/ml, BNP had 80.49% sensitivity and 90.62% specificity with a positive predictive value of 91.7% and a negative predictive value of 78.04%, (AUC: 0.923, 95% C.I. 0.837 to 0.973). Conclusion: Levels of BNP in preterm babies with hemodynamically significant PDA rise early in neonatal life and correlate well with the size of the PDA. BNP can be used to screen for this condition. Ventricular dysfunction may not appear in the first 3 days of life.
Downloads
Metrics
Plum Analytics Artifact Widget Block
References
Chen S, Tacy T, Clyman R. How useful are B-type natriuretic peptide measurements for monitoring changes in patent Ductus arteriosus shunt magnitude? J Perinatol. 2010;30(12):780-5. https://doi.org/10.1038/jp.2010.47 PMid:20376057
Hamrick SE, Hansmann G. Patent Ductus arteriosus of the preterm infant. Pediatrics. 2010;125:1020-30. https://doi.org/10.1542/peds.2009-3506 PMid:20421261
Levy PT, Dioneda B, Holland MR, Sekarski TJ, Lee CK, Mathur A, et al. Right ventricular function in preterm and term neonates: reference values for right ventricle areas and fractional area of change. J Am Soc Echocardiogr. 2015;28(5):559-69. https://doi.org/10.1016/j.echo.2015.01.024 PMid:25753503
Kozik D, Ibrahim J, Wise-Faberowski L, Ricardo A, Victor O, Educardo M. Patent Ductus arteriosus. Crit Care Children Heart Dis 2010;14:145-57. https://doi.org/10.1007/978-1-84882-262-7_14
Mertens L, Seri I, Marek J, Arlettaz R, Barker P, McNamamra P, et al. Targeted neonatal echocardiography in the neonatal intensive care unit: Practice guidelines and recommendations for training. J Am Soc Echocardiogr. 2011;24(10):1057-78. https://doi.org/10.1016/j.echo.2011.07.014 PMid:21933743
Kim J, Shim E. B-type natriuretic peptide assay for the diagnosis and prognosis of patent Ductus arteriosus in Preterm Infants. Korean Circ. 2012;42(3):192-6. https://doi.org/10.4070/kcj.2012.42.3.192 PMid:22493614
De Lemos JA, McGuire DK, Drazner MH. B-type natriuretic peptide in cardiovascular disease. Lancet. 2003;362(9380):316-22. https://doi.org/10.1016/s0140-6736(03)13976-1 PMid:12892964
Ohashi A, Kaneko K. Serum brain natriuretic peptide for prediction of successful medical treatment of patent Ductus arteriosus in premature infants. J Thorac Cardiovasc Surg. 2009;138(1):261-2. https://doi.org/10.1016/j.jtcvs.2008.09.083 PMid:19577111
Lee JH, Shin JH, Park KH, Rhie YJ, Park MS, Choi BM. Can early B-Type natriuretic peptide assays predict symptomatic patent Ductus arteriosus in extremely low birth weight infants? Neonatology. 2013;103:118-22. https://doi.org/10.1159/000343034 PMid:23182972
Ballard JL, Khoury JC, Wedig K, Wang L, Eilers-Walsman BL, Lipp R. New Ballard score, expanded to include extremely premature infants. J Pediatr. 1991;119(3):417-23. https://doi.org/10.1016/s0022-3476(05)82056-6 PMid:1880657
Esan AJ. Hematological differences in newborn and aging: A review study. Hematol Transfus Int J. 2016;3(3):178-90.
Fu L, Zhang X. Correlation between changes in brain natriuretic peptide and echocardiographic features in persistent pulmonary hypertension of newborn. J Matern Fetal Neonatal Med. 2019;33:2176-80. https://doi.org/10.1080/14767058.2018.1543392 PMid:30995876
Ko SM, Yoon YC, Cho KH, Lee Y, Han I, Park, K, et al. Primary surgical closure should be considered in premature neonates with large patent Ductus arteriosus. Korean J Thorac Cardiovasc Surg. 2013;46(3):178-84. https://doi.org/10.5090/kjtcs.2013.46.3.178
Ramos FG, Rosenfeld CR, Roy L, Koch J, Ramaciotti C. Echocardiographic predictors of symptomatic patent Ductus arteriosus in extremely-low-birth-weight preterm neonates. J Perinatol. 2010;30(8):535-9. https://doi.org/10.1038/jp.2010.14
Gaspar HA, Morhy SS. The role of focused echocardiography in pediatric intensive care: A critical appraisal. Biomed Res Int. 2015;2015:596451. https://doi.org/10.1155/2015/596451 PMid:26605333
Yokoyama U, Minamisawa S, Ishikawa Y. Regulation of vascular tone and remodeling of the Ductus arteriosus. J Smooth Muscle Res. 2010;46(2):77-87. https://doi.org/10.1540/jsmr.46.77 PMid:20551589
Drougia A, Giapros V, Krallis N, Theocharis P, Nikaki A, Tzoufi M, et al. Incidence and risk factors for cerebral palsy in infants with perinatal problems: A 15-year review. Early Hum Dev. 2007;83(8):541-7. https://doi.org/10.1016/j.earlhumdev.2006.10.004 PMid:17188824
Da Graca RL, Hassinger DC, Flynn PA, Sison CP, Nesin M, Auld PA. Longitudinal changes of brain-type natriuretic peptide in preterm neonates. Pediatrics. 2006;117(6):2183-9. https://doi.org/10.1542/peds.2005-1387 PMid:16740863
El-Khuffash A, Molloy E. Are B-type natriuretic peptide (BNP) and N-terminal-pro-BNP useful in neonates? Arch Dis Child Fetal Neonatal Ed. 2007;92(4):F320-4. https://doi.org/10.1136/adc.2006.106039 PMid:17585100
Van der Laan ME, Roofthooft MT, Fries MW, Berger RM, Schat TE, van Zoonen AG, et al. A hemodynamically significant patent Ductus arteriosus does not affect cerebral or renal tissue oxygenation in preterm infants. Neonatology. 2016;110(2):141-7. https://doi.org/10.1159/000445101 PMid:27088709
Nizarali Z, Marques T, Costa C, Barroso R, Cunha M. Patent Ductus arteriosus: Perinatal risk factors. J Neonatal Biol. 2012;1:3. https://doi.org/10.4172/2167-0897.1000109
Flynn PA, da Graca RL, Auld PA. The use of a bedside assay for plasma B-type natriuretic peptide as a biomarker in the management of patent Ductus arteriosus in premature neonates. Pediatrics. 2005;147(1):738-42. https://doi.org/10.1016/j.jpeds.2005.03.040 PMid:16027692
Konig K, Guy K, Walsh G, Drew SM, Watkins A, Barfield CP. The relationship between BNP, NTproBNP and echocardiographic measurements of systemic blood flow in very preterm infants. J Perinatol. 2014;34:296-300. https://doi.org/10.1038/jp.2014.2
Kalra V, De Bari V, Zauk A, Kataria P, Mydriakis D, Kiblawi F. Point-of-care testing for B-type natriuretic peptide in premature neonates with patent Ductus arteriosus. Ann Clin Lab Sci. 2011;41(2):131-7.
Choi BM, Lee KH, Eun BL, Yoo KH, Hong YS, Son CS. Utility of rapid B-type natriuretic peptide assay for diagnosis of symptomatic patent Ductus arteriosus in preterm infants. Pediatrics. 2005;115(3):e255-61. https://doi.org/10.1542/peds.2004-1837 PMid:15687418
Tauber K, Granina E, Doyle R, Munshi UK. Gestational and postnatal age influence B-type natriuretic peptide level used in diagnosis of a hemodynamically significant patent Ductus arteriosus in preterm infants. J Clin Neonatol. 2016;5(3):143-9. https://doi.org/10.4103/2249-4847.191241
Cuna A, Kandasamy J, Fineberg N, Sims B. B-type natriuretic peptide is a biomarker for pulmonary hypertension in preterm infants with bronchopulmonary dysplasia. Res Rep Neonatol. 2013;3:33-6. https://doi.org/10.2147/rrn.s42236
Gong H, Wang X, Shi Y, Shang WJ, Ling YI, Pan LJ, et al. Correlation between brain natriuretic peptide levels and the prognosis of patients with left ventricular diastolic dysfunction. Exp Ther Med. 2016;11(6):2583-9. https://doi.org/10.3892/etm.2016.3203 PMid:27313677
Ognean M, Boanta O, Kovacs S, Zgarcea C, Dumitra R, Olariu E, et al. Persistent Ductus arteriosus in critically Ill preterm infants. J Crit Care Med (Targu Mures). 2016;2(4):175-84. https://doi.org/10.1515/jccm-2016-0026 PMid:29967857
Steinhorn R. Neonatal pulmonary hypertension. Pediatr Crit Care Med. 2010;11(2):79-84. PMid:20216169
Lu D, Liu Y, Tong X. Clinical characteristics and cardiac hemodynamic changes of patent Ductus ateriosus in preterm infants. Zhonghua Er Ke Za Zhi. 2015;53(3):187-93. PMid:26165015
Choi BM, Lee KH, Eun BL, Yoo KH, Hong YS, Son CS, et al. Utility of rapid B-Type natriuretic peptide assay for diagnosis of symptomatic patent Ductus arteriosus in preterm infants. Pediatrics. 2005;115(3):255-61. https://doi.org/10.1542/peds.2004-1837 PMid:15687418
Cuna A, Kandasamy J, Sims B. B-type natriuretic peptide and mortality in extremely low birth weight infants with pulmonary hypertension: A retrospective cohort analysis. BMC Pediatric. 2014;14:68. https://doi.org/10.1186/1471-2431-14-68
El-Khuffash A, Molloy E. The use of N-terminal-pro-BNP in preterm infants. Int J Pediatr. 2009;2009:175216. https://doi.org/10.1155/2009/175216 PMid:20069108
Kulkarni M, Gokulakrishman G, Price J, Fernandes CJ, Leeflang M, Pammi M. Diagnosing significant PDA using natriuretic peptides in preterm. Pediatrics. 2015;135(2):e510-25. https://doi.org/10.1542/peds.2014-1995 PMid:25601976
Downloads
Published
How to Cite
Issue
Section
Categories
License
Copyright (c) 2022 Hanan Zekri, Reem N. Said, Ranya A. Hegazy, Rania K. Darwish, Abdelkarim Kamel, Nahla Gamaleldin Abd El Hakim (Author)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC 4.0)
